Errata: Oregon DUR Board Newsletter, July 2010 Volume 12, Issue 5

Combination Long-Acting Beta-Agonist and Inhaled Corticosteroid Therapy for Asthma: New Safety Concerns, Summary of Clinical Evidence and Drug Utilization Evaluation
By Dan Hartung, Pharm.D., M.P.H and Kathy Sentena, Pharm.D. both from OSU College of Pharmacy - Drug Use Research & Management

Dear Colleagues,

There is an error on page 1, paragraph 2 of the Newsletter. The SMART study was inaccurately described. We regret the error. Please see the correction below:

Inaccurate:
Controversy over the safety of treating asthma patients with LABAs has been on an ongoing discussion for 20 years. The 2007 Salmeterol Multicenter Asthma Research Trial (SMART) study included 6,112 patients over 3 years. Salmeterol plus fluticasone propionate was compared to placebo, salmeterol alone or fluticasone propionate alone. Patients taking salmeterol were noted to have a fourfold increase risk of mortality. Additional analysis suggests that the risk may be mitigated by the use of inhaled corticosteroids.

Replace with:
Controversy over the safety of treating asthma patients with LABAs has been on ongoing discussion for 20 years. The 2007 Salmeterol Multicenter Asthma Research Trial (SMART) study included 26,355 patients with asthma who were randomized to either salmeterol or placebo in addition to existing asthma treatment for up to 28 weeks. While the primary outcome, respiratory deaths or life-threatening experiences, did not reach statistical significance, subjects receiving salmeterol had a higher risk of respiratory-related deaths (RR=2.16), Asthma-related deaths (RR=4.37), and the combined outcome of asthma-related deaths or life threatening experiences (RR=1.71). While SMART was not prescriptive with respect to concurrent ICS, additional analyses suggest that the risk may be mitigated by the use of ICS.


We hope that you find this service useful and thought-provoking and we welcome your questions, concerns, comments or ideas regarding the newsletter or list.

Sincerely,

OSU College of Pharmacy - Drug Use Research & Management @
DHS Division of Medical Assistance Programs
500 Summer Street NE, E35
Salem, OR 97301-1079
osupharm.di@oregonstate.edu
Phone: 503-947-5220
Fax: 503-947-1119

---

Disclaimer: The information contained on our Web site and news list has been prepared in good faith to provide accurate and impartial information to DMAP providers. Clinical recommendations are based on published, peer-reviewed medical literature. Although every attempt has been made to ensure that the information contained herein is timely and accurate, users should consult all available sources of drug information before making decisions regarding patient care. This information is advisory only and is not intended to replace FDA-approved labeling information, or sound clinical judgment, in the delivery of health care services. Please also note that the prescribing trends provided are highly dependent on time and method of database query. The user of this information assumes entire risk.

© 2010 Oregon State University College of Pharmacy.